A Novel Predictive Multi-Marker Test for the Pre-Surgical Identification of Ovarian Cancer.
CXCL10
benign
biomarker
cancer
diagnostic
malignant
ovarian
triage
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
02 Nov 2023
02 Nov 2023
Historique:
received:
15
10
2023
revised:
27
10
2023
accepted:
27
10
2023
medline:
14
11
2023
pubmed:
14
11
2023
entrez:
14
11
2023
Statut:
epublish
Résumé
Ovarian cancer remains the most lethal of gynecological malignancies, with the 5-year survival below 50%. Currently there is no simple and effective pre-surgical diagnosis or triage for patients with malignancy, particularly those with early-stage or low-volume tumors. Recently we discovered that CXCL10 can be processed to an inactive form in ovarian cancers and that its measurement has diagnostic significance. In this study we evaluated the addition of processed CXCL10 to a biomarker panel for the discrimination of benign from malignant disease. Multiple biomarkers were measured in retrospectively collected plasma samples (
Identifiants
pubmed: 37958440
pii: cancers15215267
doi: 10.3390/cancers15215267
pmc: PMC10650329
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Ovarian Cancer Research Foundation
ID : OCRF-GA-2018-11
Organisme : National Health and Medical Research Council
ID : APP1099375
Organisme : Victorian Government's Operational Infrastructure Support Program
ID : n/a
Références
Electron Physician. 2015 Nov 20;7(7):1505-10
pubmed: 26767105
Int J Cancer. 2014 Feb 1;134(3):530-41
pubmed: 23873303
Int J Gynaecol Obstet. 2021 Oct;155 Suppl 1:61-85
pubmed: 34669199
Br J Obstet Gynaecol. 1996 Aug;103(8):826-31
pubmed: 8760716
Menopause. 2019 May;26(5):554-556
pubmed: 31022097
Cancers (Basel). 2022 Mar 31;14(7):
pubmed: 35406551
Cancer Epidemiol Biomarkers Prev. 2020 Dec;29(12):2504-2512
pubmed: 33051337
Oncology (Williston Park). 2004 Mar;18(3):343-56; discussion 358, 361-2
pubmed: 15065703
Gynecol Oncol. 2019 Jun;153(3):562-567
pubmed: 30948193
J Natl Compr Canc Netw. 2021 Feb 02;19(2):191-226
pubmed: 33545690
BMC Cancer. 2020 Apr 15;20(1):320
pubmed: 32293358
Gynecol Oncol. 2002 Jan;84(1):36-42
pubmed: 11748973
Ann Intern Med. 2023 May;176(5):596-604
pubmed: 37068275
Future Oncol. 2012 Jan;8(1):55-71
pubmed: 22149035
J Natl Cancer Inst. 2006 Feb 1;98(3):172-80
pubmed: 16449677
Obstet Gynecol. 2016 Nov;128(5):e210-e226
pubmed: 27776072
Tumour Biol. 2012 Feb;33(1):141-8
pubmed: 22105734
Tumour Biol. 2014 Jul;35(7):7249-58
pubmed: 24771264
Cancer. 2006 Feb 1;106(3):589-98
pubmed: 16369985
JAMA. 1995 Feb 8;273(6):491-7
pubmed: 7837369
Acta Obstet Gynecol Scand. 2019 Jan;98(1):24-33
pubmed: 30216407
N Engl J Med. 1983 Oct 13;309(15):883-7
pubmed: 6310399
Minerva Ginecol. 2018 Aug;70(4):385-386
pubmed: 29696943
Gynecol Oncol. 2005 Nov;99(2):447-61
pubmed: 16126262
Womens Health (Lond). 2009 Sep;5(5):565-76
pubmed: 19702455
J Clin Oncol. 2018 Jul 1;36(19):1994-2001
pubmed: 29620997
Diagnostics (Basel). 2021 Jun 07;11(6):
pubmed: 34200333
Am J Obstet Gynecol. 2023 Jun 25;:
pubmed: 37364803
J Ovarian Res. 2019 Mar 27;12(1):28
pubmed: 30917847
Cancers (Basel). 2023 Jan 21;15(3):
pubmed: 36765633
BMC Bioinformatics. 2011 Mar 17;12:77
pubmed: 21414208
Am J Obstet Gynecol. 2016 Jul;215(1):82.e1-82.e11
pubmed: 26970494
Cancer. 2012 Jan 1;118(1):91-100
pubmed: 21717433
Int J Cancer. 2022 Nov 1;151(9):1535-1541
pubmed: 35322413
Br J Obstet Gynaecol. 1990 Oct;97(10):922-9
pubmed: 2223684
J Gynecol Oncol. 2015 Jan;26(1):46-53
pubmed: 25310857
Gynecol Oncol. 2009 Jan;112(1):40-6
pubmed: 18851871
Obstet Gynecol. 2007 Jul;110(1):201-14
pubmed: 17601923
Biometrics. 1988 Sep;44(3):837-45
pubmed: 3203132
Hematol Oncol Clin North Am. 2012 Feb;26(1):93-109
pubmed: 22244664
Arch Gynecol Obstet. 2018 Jan;297(1):241-255
pubmed: 29177593